3-hydroxykynurenine has been researched along with Cognitive Decline in 2 studies
3-hydroxykynurenine: RN given refers to cpd without isomeric designation
3-hydroxykynurenine : A hydroxykynurenine that is kynurenine substituted by a hydroxy group at position 3.
hydroxykynurenine : A hydroxy-amino acid that is kynurenine substituted by a single hydroxy group at unspecified position. A "closed" class.
Excerpt | Relevance | Reference |
---|---|---|
" In individuals with prediabetes, 3-hydroxykynurenine (OR per SD 0." | 8.02 | Associations between plasma kynurenines and cognitive function in individuals with normal glucose metabolism, prediabetes and type 2 diabetes: the Maastricht Study. ( Bakker, L; Dagnelie, PC; Eussen, SJPM; Köhler, S; Midttun, Ø; Ramakers, IHGB; Schram, MT; Stehouwer, CDA; Ueland, PM; van Boxtel, MPJ; van der Kallen, CJH; van Greevenbroek, MMJ; Verhey, FRJ; Wesselius, A, 2021) |
"Several kynurenines were cross-sectionally associated with lower odds of cognitive impairment and better cognitive functioning in type 2 diabetes, while less widespread associations were seen in prediabetes." | 8.02 | Associations between plasma kynurenines and cognitive function in individuals with normal glucose metabolism, prediabetes and type 2 diabetes: the Maastricht Study. ( Bakker, L; Dagnelie, PC; Eussen, SJPM; Köhler, S; Midttun, Ø; Ramakers, IHGB; Schram, MT; Stehouwer, CDA; Ueland, PM; van Boxtel, MPJ; van der Kallen, CJH; van Greevenbroek, MMJ; Verhey, FRJ; Wesselius, A, 2021) |
"Several studies suggest a pathophysiologically relevant association between increased brain levels of the neuroinhibitory tryptophan metabolite kynurenic acid and cognitive dysfunctions in people with schizophrenia." | 7.88 | Maternal genotype determines kynurenic acid levels in the fetal brain: Implications for the pathophysiology of schizophrenia. ( Beggiato, S; Giorgini, F; Notarangelo, FM; Sathyasaikumar, KV; Schwarcz, R, 2018) |
"In individuals with type 2 diabetes, kynurenine (0." | 5.62 | Associations between plasma kynurenines and cognitive function in individuals with normal glucose metabolism, prediabetes and type 2 diabetes: the Maastricht Study. ( Bakker, L; Dagnelie, PC; Eussen, SJPM; Köhler, S; Midttun, Ø; Ramakers, IHGB; Schram, MT; Stehouwer, CDA; Ueland, PM; van Boxtel, MPJ; van der Kallen, CJH; van Greevenbroek, MMJ; Verhey, FRJ; Wesselius, A, 2021) |
" In individuals with prediabetes, 3-hydroxykynurenine (OR per SD 0." | 4.02 | Associations between plasma kynurenines and cognitive function in individuals with normal glucose metabolism, prediabetes and type 2 diabetes: the Maastricht Study. ( Bakker, L; Dagnelie, PC; Eussen, SJPM; Köhler, S; Midttun, Ø; Ramakers, IHGB; Schram, MT; Stehouwer, CDA; Ueland, PM; van Boxtel, MPJ; van der Kallen, CJH; van Greevenbroek, MMJ; Verhey, FRJ; Wesselius, A, 2021) |
"Several kynurenines were cross-sectionally associated with lower odds of cognitive impairment and better cognitive functioning in type 2 diabetes, while less widespread associations were seen in prediabetes." | 4.02 | Associations between plasma kynurenines and cognitive function in individuals with normal glucose metabolism, prediabetes and type 2 diabetes: the Maastricht Study. ( Bakker, L; Dagnelie, PC; Eussen, SJPM; Köhler, S; Midttun, Ø; Ramakers, IHGB; Schram, MT; Stehouwer, CDA; Ueland, PM; van Boxtel, MPJ; van der Kallen, CJH; van Greevenbroek, MMJ; Verhey, FRJ; Wesselius, A, 2021) |
"Several studies suggest a pathophysiologically relevant association between increased brain levels of the neuroinhibitory tryptophan metabolite kynurenic acid and cognitive dysfunctions in people with schizophrenia." | 3.88 | Maternal genotype determines kynurenic acid levels in the fetal brain: Implications for the pathophysiology of schizophrenia. ( Beggiato, S; Giorgini, F; Notarangelo, FM; Sathyasaikumar, KV; Schwarcz, R, 2018) |
"In individuals with type 2 diabetes, kynurenine (0." | 1.62 | Associations between plasma kynurenines and cognitive function in individuals with normal glucose metabolism, prediabetes and type 2 diabetes: the Maastricht Study. ( Bakker, L; Dagnelie, PC; Eussen, SJPM; Köhler, S; Midttun, Ø; Ramakers, IHGB; Schram, MT; Stehouwer, CDA; Ueland, PM; van Boxtel, MPJ; van der Kallen, CJH; van Greevenbroek, MMJ; Verhey, FRJ; Wesselius, A, 2021) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (50.00) | 24.3611 |
2020's | 1 (50.00) | 2.80 |
Authors | Studies |
---|---|
Bakker, L | 1 |
Ramakers, IHGB | 1 |
van Boxtel, MPJ | 1 |
Schram, MT | 1 |
Stehouwer, CDA | 1 |
van der Kallen, CJH | 1 |
Dagnelie, PC | 1 |
van Greevenbroek, MMJ | 1 |
Wesselius, A | 1 |
Midttun, Ø | 1 |
Ueland, PM | 1 |
Verhey, FRJ | 1 |
Eussen, SJPM | 1 |
Köhler, S | 1 |
Beggiato, S | 1 |
Notarangelo, FM | 1 |
Sathyasaikumar, KV | 1 |
Giorgini, F | 1 |
Schwarcz, R | 1 |
2 other studies available for 3-hydroxykynurenine and Cognitive Decline
Article | Year |
---|---|
Associations between plasma kynurenines and cognitive function in individuals with normal glucose metabolism, prediabetes and type 2 diabetes: the Maastricht Study.
Topics: 3-Hydroxyanthranilic Acid; Aged; Biomarkers; Blood Glucose; Cognition; Cognitive Dysfunction; Cross- | 2021 |
Maternal genotype determines kynurenic acid levels in the fetal brain: Implications for the pathophysiology of schizophrenia.
Topics: Animals; Brain; Cognitive Dysfunction; Female; Genotype; Kynurenic Acid; Kynurenine; Kynurenine 3-Mo | 2018 |